Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study

Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations

(2013) Eliford Ngaimisi et al.   PLoS One

Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women

(2012) Betty J. Dong et al.   AIDS

Antiretroviral Treatment Interruptions Predict Female Genital Shedding of Genotypically Resistant HIV-1 RNA

(2012) Susan M. Graham et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment

(2012) Jing Li et al.   PHARMACOGENOMICS

Maintaining cost-effective access to antiretroviral drug therapy through a collaborative approach to drug procurement, consensus treatment guidelines and regular audit: the experience of London HIV commissioners and providers

(2012) Claire Foreman et al.   SEXUALLY TRANSMITTED INFECTIONS

Associations Between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 Alleles in Relation to Efavirenz and Nevirapine Pharmacokinetics in HIV-Infected Individuals

(2012) Sandra G. Heil et al.   THERAPEUTIC DRUG MONITORING

Pharmacogenetics of Toxicity, Plasma Trough Concentration and Treatment Outcome with Nevirapine-Containing Regimen in Anti-Retroviral-Naïve HIV-Infected Adults: An Exploratory Study of the TRIANON ANRS 081 Trial

(2011) Claire Gozalo et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Functional Characterization of CYP2B6 Allelic Variants in Demethylation of Antimalarial Artemether

(2011) M. Honda et al.   DRUG METABOLISM AND DISPOSITION

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals

(2011) A. Schipani et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients

(2011) A. Habtewold et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Resistance Patterns Selected by Nevirapine vs. Efavirenz in HIV-Infected Patients Failing First-Line Antiretroviral Treatment: A Bayesian Analysis

(2011) Nicole Ngo-Giang-Huong et al.   PLoS One

Incidence and risk factors of antiretroviral treatment failure in treatment-naïve HIV-infected patients at Chiang Mai University Hospital, Thailand

(2011) Nitta Khienprasit et al.   AIDS Research and Therapy

Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml

(2010) Stéphanie Haïm-Boukobza et al.   AIDS

Long-Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients

(2010) E Ngaimisi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Sustainability of First-Line Antiretroviral Regimens: Findings From a Large HIV Treatment Program in Western Kenya

(2010) Paula Braitstein et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Antiretroviral Adherence and Development of Drug Resistance Are the Strongest Predictors of Genital HIV‐1 Shedding among Women Initiating Treatment

(2010) Susan M. Graham et al.   JOURNAL OF INFECTIOUS DISEASES

Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population

(2009) TW Mahungu et al.   HIV MEDICINE

Associations betweenCYP2B6Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African Americans

(2009) David W. Haas et al.   JOURNAL OF INFECTIOUS DISEASES

Establishment of a biobank and pharmacogenetics database of African populations

(2008) Alice Matimba et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients

(2008) C. Wyen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY